Billings Clinic
Especially For:

Clinical Trials

Title   GI: Metastatic Neuroendocrine Carcinoma of the Pancreas
Description   Randomized Phase II Study of Everolimus Alone Versus Everolimus Plus Bevacizumab in Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors
IRB Number   CTSU C80701
Category   Gastrointestinal
Inclusion/Notes   1. Histologic documentation of well differentiated or moderately differentiated neuroendocrine tumor from either a primary or metastatic site. Must have either histologic documentation of a pancreatic primary site, or clinical evidence of a pancreatic neuroendocrine primary tumor as determined by the treating physician.
2. Measurable or nonmeasureable disease.




Please contact Tricia Montgomery, RN for additional inclusion/exclusion criteria.
Status   Open
Start Date   12/10/2010
Principal Investigator (PI)   Jorge Nieva, MD
Contact Name   Tricia Montgomery
Contact Email   tmontgomery@billingsclinic.org
Phone   (406) 435-7483
Alternate Phone   (406) 435-7480
Fax   (406) 435-7489
Print This Page
Email to a Friend
Home | Contact | Site Map | Site Privacy Policy | Terms & Conditions | Patient Privacy Policy | Medical Records | Fast Command
2800 10th Ave. North | P.O. Box 37000 | Billings, Montana 59107 | 406.238.2500
© Copyright 2014 Billings Clinic. All Rights Reserved.